Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | CRHBP | P24387 | 1/20 | 0.42 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24595190 | 0.84 | MAPT (0.47) | KMT2ACYP1A2MAPTCYP2D6MEN1 | |
| SCHEMBL29610649 | 0.81 | MAPT (0.49) | KMT2ACYP1A2MAPTCYP2D6MEN1 | |
| SCHEMBL24312193 | 0.81 | MAPT (0.49) | KMT2ACYP1A2MAPTCYP2D6MEN1 | |
| SCHEMBL24312231 | 0.81 | KMT2A (0.44) | KMT2ACYP1A2MAPTCYP2D6MEN1 | |
| SCHEMBL24312280 | 0.80 | RAF1 (0.44) | KMT2ACYP1A2MAPTCYP2D6MEN1 | |
| SCHEMBL17204101 | 0.79 | MAPT (0.61) | KMT2ACYP1A2MAPTCYP2D6MEN1 | |
| SCHEMBL29611284 | 0.78 | MAPT (0.44) | KMT2ACYP1A2MAPTCYP2D6MEN1 | |
| SCHEMBL24312249 | 0.78 | MAPT (0.44) | KMT2ACYP1A2MAPTCYP2D6MEN1 | |
| SCHEMBL24312188 | 0.76 | MAPT (0.39) | KMT2ACYP1A2MAPTCYP2D6MEN1 | |
| SCHEMBL24312185 | 0.76 | CYP1A2 (0.39) | KMT2ACYP1A2MAPTCYP2D6MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746095-B2 | Inhibtors of RAF kinases | KINNATE BIOPHARMA INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11746095-B2 | Inhibtors of RAF kinases | KINNATE BIOPHARMA INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11746095-B2 | Inhibtors of RAF kinases | KINNATE BIOPHARMA INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20220356160-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2022-11-10 | — | — | US | disclosed |
| US-11407737-B2 | Inhibitors of RAF kinases | KINNATE BIOPHARMA INC. (US) | 2022-08-09 | — | — | US | disclosed |
| US-11377431-B2 | Inhibitors of RAF kinases | KINNATE BIOPHARMA INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-11377431-B2 | Inhibitors of RAF kinases | KINNATE BIOPHARMA INC. (US) | 2022-07-05 | — | — | US | disclosed |
| WO-2022081469-A1 | INHIBITORS OF RAF KINASES | KINNATE BIOPHARMA INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022081469-A1 | INHIBITORS OF RAF KINASES | KINNATE BIOPHARMA INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| US-20220112170-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2022-04-14 | — | — | US | disclosed |
| US-20220112170-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112170-A1 | INHIBITORS OF RAF KINASES | BRAF, RAF1, ARAF | KMT2A 1631/4885CYP1A2 4302/4885MAPT 2859/4885 |
| US-11407737-B2 | Inhibitors of RAF kinases | BRAF, RAF1, ARAF | KMT2A 1631/4885CYP1A2 4302/4885MAPT 2859/4885 |
| US-11746095-B2 | Inhibtors of RAF kinases | RAF1, BRAF, ARAF | KMT2A 2824/4885CYP1A2 4124/4885MAPT 3440/4885 |
| US-20220356160-A1 | INHIBITORS OF RAF KINASES | BRAF, RAF1, ARAF | KMT2A 1631/4885CYP1A2 4302/4885MAPT 2859/4885 |
| US-11377431-B2 | Inhibitors of RAF kinases | BRAF, RAF1, ARAF | KMT2A 1631/4885CYP1A2 4302/4885MAPT 2859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.